Genistein, a naturally occurring isoflavone, possesses many beneficial health effects. To improve the bioactivity of the natural compound, we designed and synthesized the genistein prodrug FEHH6-1. In the present study, we evaluated the biological effects of FEHH6-1 on mouse RAW264.7 macrophages and compared them with those obtained with the parent drug genistein. The characteristics of FEHH6-1 were determined by melting point, nuclear magnetic resonance spectroscopy (NMR), and mass spectrometric analysis. The effects of FEHH6-1 on cell proliferation, apoptosis, and pro-inflammatory cytokine expression were monitored by XTT-assay, Annexin-V/7-AAD staining, Western blotting, and ELISA. FEHH6-1 showed NMR spectra and relative molecular mass in agreement with the designed structure. In mouse RAW264.7 macrophages, FEHH6-1 inhibited proliferation, induced apoptotic cell death and blocked interleukin 6 and tumor necrosis factor alpha synthesis. At low concentrations, FEHH6-1 induced phosphorylation of AKT1, a kinase involved in cell proliferation and survival. Our data demonstrate that the genistein prodrug FEHH6-1 is a bioactive molecule but its solubility and therefore also its efficacy was significantly lower compared with genistein.
Genistein (4´,5,7-trihydroxyisoflavone) is a phytoestrogen that belongs to the category of isoflavones. Since the 1980s, numerous studies have reported on the anti-inflammatory, anti-oxidant and anti-cancer activities of genistein. Akiyama et al. found that genistein, the principal isoflavone in soy, is a potent and specific in vitro inhibitor of the activity of the epidermal growth factor tyrosine kinase [1] . Since this discovery, there has been a literature explosion on the use of genistein to explore tyrosine phosphorylation events in signal transduction pathways in many cell types. In RAW264.7 macrophages, genistein suppressed lipopolysaccharide-induced inflammatory response through inhibiting nuclear factor kappa B (NF-κB) activation following AMP kinase activation [2] . Genistein has been demonstrated to suppress the proliferation of various tumor cell lines including breast cancer, prostate cancer, head and neck squamous cell carcinoma, melanoma and leukemia [3] [4] [5] . Studies have reported that genistein suppressed tumor cell growth through the inhibition of tyrosine protein kinases [6a] , topoisomerase I and II [6b,7] and the expression of mRNAs of cell cycle-related genes [8] . In prostate cancer cells, genistein triggered cell cycle arrest and apoptotic cell death through inactivation of NF-κB and activation of caspase-3 [9, 10] . Treatment of Jurkat leukemia T cells with genistein led to G 2 /M arrest at low concentrations (5 -10 µg/mL), while at higher doses (20 -30 µg/mL) a pertubation in S-phase progression was observed followed by apoptotic cell death [4] . As a result of the very promising in vitro studies, the effectiveness of genistein in the diet was tested in various animal models of cancer. Cancer studies included those of bladder, breast, colon, liver, lung, prostate and skin. Interestingly, 17 of 26 studies reported a protective effect of soy [11a] . Clinical evidence for genistein as an effective supplement for cancer prevention and treatment in humans is rare. In 2012, a first phase II cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in 59 patients diagnosed with urothelial bladder . In this study, 300/600 mg genistein/day was given to patients for 14 to 21 days before surgery. Data show that reduction in bladder cancer tissue phospho (p)-epidermal growth factor receptor (EGFR) staining between the placebo group and the 300 mg genistein group was most prominent, but there was no significant reduction in p-EGFR staining between the 600 mg genistein group and placebo, suggesting that genistein might display a bimodal effect (more effective at the lower dose) on bladder cancer tissue EGFR phosphorylation [11b].
In an effort to improve the pharmacological efficacy of genistein, we designed and synthesized the genistein analog FEHH6-1 based on the concept of a prodrug. Through esterification of the phenolic groups, a greater resistance to oxidative processes and an increase in lipophilicity was achieved. To convert the inactive prodrug into its active variant, FEHH6-1 has to be cleaved through intracellular esterases, promising an amplification of the bioactivity compared with the parent drug genistein. In the present study, we investigated the biological effects of FEHH6-1 on mouse RAW264.7 macrophages and compared the data with those obtained with the naturally occurring compound genistein.
FEHH6-1 inhibits proliferation of mouse RAW264.7 macrophages:
Previous studies have demonstrated that genistein NPC Natural Product Communications 2016 Vol. 11 No. 10 1437 -1440 has potent anti-proliferative and pro-apoptotic effects on numerous cancer cell lines. To assess the influence of FEHH6-1 and genistein on the growth of RAW264.7 macrophages, the cells were exposed for 24 h to increasing concentrations (1 -50 µM) of each compound. This concentration range is also in good agreement with the amount of genistein used in the mentioned clinical trial [11b] . After the addition of XTT-reagent, the cells were incubated for another 6 h and absorption was measured at 490/655 nm. Data show that FEHH6-1 (25 µM) reduced proliferation of RAW264.7 macrophages by about 50%; genistein, however, by about 90% (Figure 2 ), revealing potent anti-proliferative activities of both compounds on RAW264.7 macrophages. An important observation may explain the lower efficacy of FEHH6-1: We observed that at a concentration of 25 µM, FEHH6-1 started to precipitate, at 50 µM, it was insoluble and precipitated in the form of crystals. 
FEHH6-1 induces apoptotic cell death in mouse RAW264.7 macrophages:
To investigate the ability of FEHH6-1 and its parent drug genistein to induce apoptosis in mouse RAW264.7 macrophages, the cells were treated for 48 h with increasing concentrations (1 -50 µM) of each compound. Thereafter, the cells were labelled with Annexin-V/7-AAD to analyze ongoing apoptotic processes. We observed that up to 10 µM, both FEHH6-1 and genistein did not negatively affect cell viability of RAW264.7 macrophages ( Figure 3A , B). At 25 µM FEHH6-1, about 60% of the cells were alive, 5% were in the early apoptotic and 30% in the late apoptotic/dead stage. Treatment of the cells with higher concentrations of FEHH6-1 (50 µM) did not lead to a further increase in the percentage of apoptotic/dead cells ( Figure 3A ) due to the low solubility of FEHH6-1 in aqueous solutions. At 25 µM genistein, about 30% of the cells were alive, 15% were in the early apoptotic and 50% already in the late apoptotic/dead stage ( Figure  3B ). At 50 µM genistein, almost the whole cell population was in the late apoptotic/dead stage, revealing a significantly higher proapoptotic potential of the natural compound compared with FEHH6-1. Importantly, in peripheral blood mononuclear cells (PBMCs) from healthy donors, both FEHH6-1 and genistein did not affect cell viability (Fig. 3C, D) .
FEHH6-1 induces phosphorylation of AKT1 in mouse RAW264.7 macrophages:
AKT kinase (AKT1) plays a central role in cell proliferation and survival, cell migration and angiogenesis. To investigate whether FEHH6-1 and genistein modulates AKT1 activation, RAW264.7 macrophages were exposed for 48 h to increasing concentrations (1 -25 µM) of each compound. Phosphorylation of AKT1 at Ser473 was analysed by Western blotting. We observed that in RAW264.7 macrophages treated with either FEHH6-1 or genistein, phosphorylation of AKT1 dosedependently increased ( Figure 4A, B ), suggesting a protective role of both substances at low concentrations (10 -15 µM). At 15 and 25 µM FEHH6-1, AKT1 was phosphorylated to a similar extent, whereas at 25 µM genistein, phosphorylation of AKT1 in turn decreased ( Figure 4A, B ). In addition, expression and cleavage products of the apoptotic marker proteins caspase-3 and -7 were analysed. In cells treated with vehicle only, cleavage products of caspase-3/-7 (17 and 20 kDa, respectively) were detected ( Figure  4C ), but they disappeared by treatment of the cells with 10 and 15 µM of either FEHH6-1 or genistein, confirming the protective role (caspase inhibition?) of both compounds at low concentrations. 
FEHH6-1 diminishes pro-inflammatory cytokine expression in mouse RAW264.7 macrophages:
To evaluate the antiinflammatory potential of FEHH6-1 and genistein in RAW264.7 macrophages, the cells were stimulated for 24 h with LPS with or without different concentrations (1 -50 µM) of each compound. In macrophages, treatment with 10 µM FEHH6-1 or genistein, IL-6 levels were reduced by about 65% and 80%, respectively ( Figure  5A ). Considering TNF-α levels, the inhibitory effect of genistein was significantly more pronounced compared with FEHH6-1; 40% versus 25% inhibition ( Figure 5B ), revealing a potent antiinflammatory potential of both compounds. Genistein is a naturally occurring phytoestrogen present in different plant species including lupin, fava beans, soybeans, kudzu, and psoralea. Many studies have described its anti-oxidant [12a] , antiinflammatory [2] and anti-cancer activities [3-5]. In the intention to improve the pharmacological potential of genistein, we designed and chemically synthesized the genistein prodrug FEHH6-1. Esterification of the phenolic groups may make FEHH6-1 more resistant to oxidative processes and may improve the bioavailability of the natural compound. In the present study, we compared the anti-proliferative, pro-apoptotic and anti-inflammatory properties of FEHH6-1 with the parent drug genistein on mouse RAW264.7 macrophages. The mouse macrophage cell line RAW264.7 is a recognized and representative in vitro model to study the effects of natural and synthetic compounds on cell proliferation, apoptosis and inflammation. It should be noted that RAW264.7 macrophages have a leukemic background and results can only be partially transferred to cells from healthy donors. In RAW264.7 macrophages, both FEHH6-1 and genistein effectively inhibited proliferation, induced apoptotic cell death and diminished pro-inflammatory cytokine expression. At low concentrations (10 µM) the anti-proliferative effects of FEHH6-1 and genistein were quite similar, at higher concentrations (25 -50 µM), however, genistein was significantly more effective than the prodrug FEHH6-1 because FEHH6-1 was insoluble at these concentrations. Similar effects were observed when the pro-apoptotic potential of FEHH6-1 and genistein was evaluated. At 25 µM, genistein was twice as effective in inducing apoptosis as FEHH6-1, confirming the enhanced activities of genistein compared with FEHH6-1. In peripheral blood mononuclear cells from healthy donors, however, FEHH6-1 and genistein did not negatively affect cell viability, suggesting that FEHH6-1 and genistein specifically induced apoptosis only in transformed cells. Furthermore, we observed that by treatment of RAW264.7 macrophages with low concentrations (10 -15 µM) of either FEHH6-1 or genistein, phosphorylation of AKT1 increased. AKT1 kinase negatively regulates pro-apoptotic proteins by direct phosphorylation. For example, it phosphorylates BAD on Ser136 [12b], which makes BAD dissociate from the Bcl-2/Bcl-xL complex and lose the pro-apoptotic function. In addition, AKT1 phosphorylates caspase-9 on Ser196, preventing a caspase cascade leading to cell death [12c]. Furthermore, it has been reported that genistein also prolonged life span in Drosophila melanogaster [13] , suggesting that genistein and its analogues are substances with antiapoptotic and anti-aging properties, worth studying in further experiments.
Besides the anti-proliferative and pro-apoptotic effects of FEHH6-1 and genistein on RAW264.7 macrophages, both compounds showed potent anti-inflammatory activities on this cell type. IL-6 and TNFα were significantly down-regulated at relatively low concentrations (10 µM), but the inhibition of IL-6 expression was more pronounced than that of TNF-α.
The major findings of the present study were as follows: 1) the genistein prodrug FEHH6-1 was designed and successfully synthesized; 2) its biological properties were investigated in vitro using the mouse macrophage cell line RAW264.7; 3) the results were evaluated and compared with those obtained with the parent drug genistein; 4) the data clearly demonstrate that at higher concentrations the bioactivity of FEHH6-1 was significantly lower compared with genistein, most likely due to its poor solubility in aqueous solutions.
Experimental:
Chemicals and equipment: Melting points, ThermoGalen Kofler hot stage microscope; NMR, Bruker Advance (200/50 MHz); MS, Shimadzu spectrometer (GC-17A; MS-QP5050A); Combustion analysis, Perkin-Elmer 2400 CHN elemental analyzer; TLC, silica gel F254 coated aluminum sheets (Merck); CC, silica gel 60 (70 -230 mesh) ASTM (Merck).
Synthesis of FEHH6-1:
To a solution of genistein (10 mmol) in dry tetrahydrofuran (2 mL), stirred at 0°C under argon atmosphere, a suspension of sodium hydride (40 mmol) was added. After 20 min, 50 mmol ethyl chloroformate was added and the reaction mixture was allowed to reach room temperature (rt). After 60 min at rt, the reaction mixture was filtered under reduced pressure. The solvent of the filtrate was removed in vacuo and the crude product was purified by column chromatography (toluene/ethyl acetate: 20 + 1). FEHH6-1 was characterized by 1 H HMR, 13 Laboratories, Inc., Hercules, CA, USA) using the Trans-Blot ® Turbo TM Transfer System (Bio-Rad). The membranes were blocked for 1 h with 5%, w/v, non-fat dry milk in PBS containing 0.1%, v/v, Tween 20 (PBST) and probed overnight at 4°C with specific antibodies to caspase-3/-7, AKT1, phospho-AKT1 (Ser473) (Cell Signaling, New England Biolabs, Frankfurt am Main, Germany), and Tubulin (Sigma-Aldrich). The blots were washed 3 x 5 min with PBST and incubated for 2 h with horseradish peroxidase-coupled anti-rabbit secondary antibody in PBST containing 1%, w/v, non-fat dry milk. Finally, the membranes were washed 3 x 5 min with PBST and developed with the WesternBright TM ECL-spray (Advansta Inc., Menlo Park, CA, USA). The signals were detected with the GeneGnome device (Syngene, Cambridge, UK).
Stimulation of cells and quantification of cytokine expression:
Mouse RAW264.7 macrophages were seeded in 12-well plates (1 x 10 5 cells/well) and stimulated for 24 h with lipopolysaccharide (LPS; 100 ng/mL). The concentrations of interleukin (IL-) 6, and tumor necrosis factor alpha (TNF-α) in cell culture supernatants were quantified by enzyme-linked immunosorbent assay (ELISA) obtained from eBioscience (San Diego, CA, USA) and used according to the manufacturer´s instructions.
Statistical analysis:
The results are expressed as the mean ± standard error of the mean (SEM). Statistical differences within groups were evaluated by either one-factor analysis of variance (ANOVA) or two-way ANOVA followed by post-hoc analysis using Bonferroni test as appropriate. A value of p< 0.05 was considered statistically significant.
